Developing countries are seeking to pay as little as 1 percent of the $84,000 price Gilead Sciences Inc. is charging U.S. patients for its new hepatitis C drug. Wealthier countries such as Ukraine and China may not be so lucky, according to Doctors Without Borders, the nonprofit international aid group.
Express Scripts Holding Co., a pharmacy benefit manager that handles more than 1 billion prescriptions annually in the U.S., is ratcheting up its effort to force Gilead Sciences Inc. to cut the $84,000 price of its new hepatitis C pill Sovaldi.
Retailers including Wal-Mart Stores Inc. and Target Corp. were handed a defeat by a U.S. appeals court, which upheld Federal Reserve rules governing how much banks can collect for debit-card transactions.
Google Inc., owner of the most-used search engine, must face revived claims that its Street View mapping system infringed a California company’s patents for creating images for visually navigating a geographic area.